Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation for Prostate Cancer

This study is to investigate the how well it works of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

Official registry: https://clinicaltrials.gov/study/NCT06262633 · Chinese University of Hong Kong · enrollment listed as 110

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation. The registry lists allocation as na. This study is to investigate the how well it works of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

They plan to enroll about 110 people at Shatin. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation: The VIOLETTA Trial

Interventions: Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation

Primary outcome (registry wording): The oncological control of prostate cancer

Who it is for (from inclusion criteria)

  • Ages 50 Years to any
  • Men only
  • ISUP grade group 2 or 3 PCa
  • Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed
  • Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed

Public study contact (from the registry)

Peter Ka-Fung CHIU, PhD,MBChB

35052625

peterchiu@surgery.cuhk.edu.hk

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT06262633 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06262633?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06262633?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary